CO2 Solutions Receives Purchase Order for Enzymes

TSX-V: CST

Corporation explores opportunities in high potential algae and biofuels production segment

QUEBEC CITY, Feb. 14, 2017 /CNW Telbec/ - CO2 Solutions Inc. (TSXV: CST), the leader in the field of enzyme-enabled carbon capture technology, today announced that the Corporation has received a purchase order from a third party for the sale, by CO2 Solutions, of carbonic anhydrase enzyme ("CA") for the use in CO2 capture for enhancing the growth of algae for economical, sustainable production of protein and biofuel products. The purchase order is for the sale of US $37,500 of enzyme to be delivered immediately. The name of the company purchasing the enzyme is not disclosed for competitive reasons. 

This sale of CA to this leading provider of innovative technology is a trial to quantify the benefits of using CA to enhance the production of algae. A positive result of this CA trial and the commercialization of this algae-based technology could lead to further sales of CA. Algae cultivation and processing is considered as an environmentally attractive method to produce biofuel and other value-added bio-products.

"While CO2 capture and reuse is our current focus, there are other market applications for robust and low-cost carbonic anhydrase enzyme, such as its use for algae production, which are covered by our intellectual property," stated Evan Price, President and CEO of CO2 Solutions Inc. "We are well positioned to serve these markets and look forward to working with this company and others in the high potential algae and biofuel production segment."

About CO2 Solutions Inc.
CO2 Solutions is an innovator in the field of enzyme-enabled carbon capture and has been actively working to develop and commercialize the technology for stationary sources of carbon pollution. CO2 Solutions' technology lowers the cost barrier to Carbon Capture, Sequestration and Utilization (CCSU), positioning it as a viable CO2 mitigation tool, as well as enabling industry to derive profitable new products from these emissions. COSolutions has built an extensive patent portfolio covering the use of carbonic anhydrase, or analogues thereof, for the efficient post‐combustion capture of carbon dioxide with low‐energy aqueous solvents. Further information can be found at www.co2solutions.com.

CO2 Solutions Forward-looking Statements
Certain statements in this news release may be forward-looking. These statements relate to future events, including statements relating to the liquidation of Akermin, or CO2 Solutions' future economic performance, and reflect the current assumptions and expectations of management. Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, general business and economic uncertainties, third party events and adverse market conditions as well as those risks set out in the Corporation's public documents filed on SEDAR. Readers are cautioned not to place undue reliance on such forward-looking statements. CO2 Solutions undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE CO2 Solutions Inc.

For further information: Investor Relations and Media Contact: CO2 Solutions, Thom Skinner, 418-842-3456, ext. 223, thom.skinner@co2solutions.com, www.co2solutions.com; or NATIONAL Equicom, Marc Lakmaaker, 416-848-1397, mlakmaaker@national.ca

RELATED LINKS
www.co2solutions.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890